SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
COMMACK, NY, July 13, 2017 -- A spacious, technologically advanced facility, conveniently located within an area of robust pharmaceutical initiatives, is now available for cGMP activities, from formulation development to mid-size commercial production. Ropack Pharma Solutions (RPS) has made the strategic decision to market and sell its 103,530-sq-ft pharmaceutical and research facility on a 10.75-acre plot at 49 Mall Drive, Commack, New York.
|
|||
The well-maintained facility has benefited from $50M in capital investments in the past 10 years. It houses 16 process development and commercial manufacturing suites as well as full-fit-out analytical laboratories. This facility has fully validated HVACs, temperature- and humidity-controlled production suites, USP water system, compressed air, laboratories, cGMP-qualified manufacturing clean rooms and warehouses. Complete equipment train and lab devices allow the capacity to perform a wide range of cGMP activities.
“We operated in this facility with the belief that advanced technology brings advanced results,” said Yves Massicotte, President and CEO of RPS. “We have applied this principle in keeping the labs pristine and production suites equipped, fully commissioned utility systems and technology from the most-respected names in the industry to meet cGMP requirements.”
With an excellent regulatory history; DEA Schedule II-V license; up to 40,000 sq. ft. of warehouse expansion possible on available land; and immediate, easy freeway access (I-495), the 49 Mall Drive location has the capacity, technology and amenities to meet the most exacting requirements.
Interested parties should contact Yves Massicotte for more information regarding an acquisition of this Commack, New York-based solid dosage development and manufacturing facility. For more information visit http://www.ropack.com/2017/06/13/available/
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/0628c545-bf6d-40ab-b9cb-203097df7bea
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0200cfa6-1881-4b51-956d-98261484ec5d
Yves Massicotte, President and CEO Ropack Pharma Solutions 1-888-353-7090, ext. 2271 [email protected] Josee LeBlanc, Assistant to the President and CEO Ropack Pharma Solutions 1-888-353-7090, ext. 2271 [email protected]
